Condition: Breast Cancer Stage IV · Sponsor: SOLTI Breast Cancer Research Group
This is an open-label, single arm, non-randomized, multicenter, phase 2 study assessing the efficacy and safety of T-DXd as first-line treatment in HER2-positive advanced/metastatic BC patients (N=300). The study integrates digital health tools for proactive toxicity management and potentially facilitate early detection of ILD/pneumonitis.
This description comes directly from the study's public registry record.
Mariana Paes Dias, PhD · +34 933 436 302 · info@gruposolti.org
Always discuss trial participation with your own doctor first.
| Gustave Roussy | Villejuif, France | Not Yet Recruiting |
| Klinikum der Universitaet Muenchen AöR | München, Germany | Not Yet Recruiting |
| Hospital Universitari Vall d'Hebrón | Barcelona, Barcelona, Spain | Recruiting |
| Complexo Hospitalario Universitario A Coruna | A Coruña, Spain | Not Yet Recruiting |
| Hospital General Universitario Dr. Balmis | Alicante, Spain | Recruiting |
| Hospital Universitario de Badajoz | Badajoz, Spain | Recruiting |
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital Universitario de Basurto | Bilbao, Spain | Not Yet Recruiting |
| Institut Català d'Oncologia (ICO) Girona | Girona, Spain | Not Yet Recruiting |
| Hospital Universitario Clínico San Cecilio | Granada, Spain | Recruiting |
| Institut Català d'Oncologia (ICO) Hospitalet | L'Hospitalet de Llobregat, Spain | Not Yet Recruiting |
| Hospital Universitario Leon | León, Spain | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07371585